RecruitingPhase 3NCT06016842
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
Studying Primary biliary cholangitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ipsen
- Principal Investigator
- Ipsen Medical DirectorIpsen
- Intervention
- Elafibranor(drug)
- Enrollment
- 276 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2029
Study locations (30)
- Arizona Liver Health, Tucson, Arizona, United States
- Arkansas Diagnostic Center, PA, Little Rock, Arkansas, United States
- Southern California Research Center, Coronado, California, United States
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- GastroIntestinal BioSciences, Los Angeles, California, United States
- University of California Los Angeles, Los Angeles, California, United States
- University of California Davis Medical Center, Sacramento, California, United States
- University of Colorado, Aurora, Colorado, United States
- Peak Gastroenterology Associates, Colorado Springs, Colorado, United States
- South Denver Gastroenterology, P.C., Englewood, Colorado, United States
- Rocky Mountain Gastroenterology, Littleton, Colorado, United States
- University Of Miami School Of Medicine, Center For Liver Diseases, Miami, Florida, United States
- Bolanos Clinical Research, Pembroke Pines, Florida, United States
- International Center for Research, Tampa, Florida, United States
- University of Kansas Medical Center (KUMC) - University of Kansas Liver Center - Hepatology Clinic, Kansas City, Kansas, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06016842 on ClinicalTrials.govOther trials for Primary biliary cholangitis
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07449793Biochemical Response and Clinical Outcomes in Patients With PBCRenJi Hospital
- RECRUITINGPHASE3NCT07296458FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC TherapyXijing Hospital of Digestive Diseases
- RECRUITINGPHASE3NCT07282353A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCACascade Pharmaceuticals, Inc
- RECRUITINGNCT07205874Early Diagnosis of Primary Biliary Cholangitis (PBC) in Patients With Positive Anti-Mitochondrial Antibodies (AMA) and Normal Alkaline Phosphatase (ALP)Hospital Universitario La Paz
- ACTIVE NOT RECRUITINGNCT07049887A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria)Ipsen
- RECRUITINGNCT07149675PBC Long-term Outcomes StudyBeijing Friendship Hospital
- RECRUITINGEARLY PHASE1NCT07104201Fenofibrate in Subjects With Primary Biliary Cholangitis (PBC)Xijing Hospital of Digestive Diseases
- RECRUITINGNANCT06861465EMPower MechanismsUniversity of Alberta